JP2006517976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517976A5 JP2006517976A5 JP2006503591A JP2006503591A JP2006517976A5 JP 2006517976 A5 JP2006517976 A5 JP 2006517976A5 JP 2006503591 A JP2006503591 A JP 2006503591A JP 2006503591 A JP2006503591 A JP 2006503591A JP 2006517976 A5 JP2006517976 A5 JP 2006517976A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- substituted
- optionally substituted
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 152
- 150000001875 compounds Chemical class 0.000 claims 71
- 125000001072 heteroaryl group Chemical group 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 46
- 239000001257 hydrogen Substances 0.000 claims 45
- 229910052739 hydrogen Inorganic materials 0.000 claims 45
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 28
- 150000002431 hydrogen Chemical class 0.000 claims 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
- 229910052736 halogen Inorganic materials 0.000 claims 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 13
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 206010040070 Septic Shock Diseases 0.000 claims 9
- 206010003246 arthritis Diseases 0.000 claims 9
- 125000003107 substituted aryl group Chemical group 0.000 claims 9
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 claims 7
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 6
- 206010035664 Pneumonia Diseases 0.000 claims 6
- 206010040047 Sepsis Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 208000002780 macular degeneration Diseases 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- -1 —C (O) Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010063094 Cerebral malaria Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000018652 Closed Head injury Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012442 Dermatitis contact Diseases 0.000 claims 3
- 206010014824 Endotoxic shock Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 201000005569 Gout Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 201000009906 Meningitis Diseases 0.000 claims 3
- 206010027476 Metastases Diseases 0.000 claims 3
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 3
- 208000033464 Reiter syndrome Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 201000010001 Silicosis Diseases 0.000 claims 3
- 206010042496 Sunburn Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 3
- 206010048873 Traumatic arthritis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 3
- 230000002491 angiogenic effect Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 208000019664 bone resorption disease Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 3
- 210000000078 claw Anatomy 0.000 claims 3
- 208000010247 contact dermatitis Diseases 0.000 claims 3
- 210000004351 coronary vessel Anatomy 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 210000002216 heart Anatomy 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 3
- 208000002574 reactive arthritis Diseases 0.000 claims 3
- 208000037803 restenosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 201000005404 rubella Diseases 0.000 claims 3
- 230000036303 septic shock Effects 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 201000004595 synovitis Diseases 0.000 claims 3
- 230000004614 tumor growth Effects 0.000 claims 3
- 230000003519 ventilatory effect Effects 0.000 claims 3
- PYQCKLNGCQVGFP-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1,3-dihydroxypropan-2-ylamino)-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(NC(CO)CO)=CC=2N1C1=CC=CC=C1Cl PYQCKLNGCQVGFP-UHFFFAOYSA-N 0.000 claims 2
- AHUOKSBJVXQBQH-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1,3-dihydroxypropan-2-ylamino)quinolin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=CC(NC(CO)CO)=CC=1C1=CC=CC=C1Cl AHUOKSBJVXQBQH-UHFFFAOYSA-N 0.000 claims 2
- RBYQNKUAGUQDAA-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1h-imidazol-2-ylmethylamino)-1,6-naphthyridin-2-one Chemical compound ClC1=CC=CC=C1C1=NC(NCC=2NC=CN=2)=CC2=C1C=CC(=O)N2C1=CC=CC=C1Cl RBYQNKUAGUQDAA-UHFFFAOYSA-N 0.000 claims 2
- UTEMMEATFDOJTF-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-[2-(propan-2-ylamino)ethylamino]-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(NCCNC(C)C)=CC=2N1C1=CC=CC=C1Cl UTEMMEATFDOJTF-UHFFFAOYSA-N 0.000 claims 2
- WLVWEQBXJOIHES-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-[2-(propan-2-ylamino)ethylamino]quinolin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=CC(NCCNC(C)C)=CC=1C1=CC=CC=C1Cl WLVWEQBXJOIHES-UHFFFAOYSA-N 0.000 claims 2
- GMZQTGQJWIBEEA-UHFFFAOYSA-N 1,5-bis(4-fluorophenyl)-1,8-naphthyridin-2-one Chemical compound C1=CC(F)=CC=C1C1=CC=NC2=C1C=CC(=O)N2C1=CC=C(F)C=C1 GMZQTGQJWIBEEA-UHFFFAOYSA-N 0.000 claims 2
- FGRCFQSRHJPOOF-UHFFFAOYSA-N 1,5-bis(4-fluorophenyl)quinolin-2-one Chemical compound C1=CC(F)=CC=C1C1=CC=CC2=C1C=CC(=O)N2C1=CC=C(F)C=C1 FGRCFQSRHJPOOF-UHFFFAOYSA-N 0.000 claims 2
- NCVGTRDMXZGULL-UHFFFAOYSA-N 1-(4-fluorophenyl)-5-(4-methylphenyl)quinolin-2-one Chemical compound C1=CC(C)=CC=C1C1=CC=CC2=C1C=CC(=O)N2C1=CC=C(F)C=C1 NCVGTRDMXZGULL-UHFFFAOYSA-N 0.000 claims 2
- YGRYGQKVGGEPER-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-1-(4-fluorophenyl)-1,8-naphthyridin-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C(C=3C(=CC(F)=CC=3)F)C=CN=C21 YGRYGQKVGGEPER-UHFFFAOYSA-N 0.000 claims 2
- LIYRXUGPUPJBLG-UHFFFAOYSA-N 5-(2,4-difluorophenyl)-1-(4-fluorophenyl)quinolin-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C(C=3C(=CC(F)=CC=3)F)C=CC=C21 LIYRXUGPUPJBLG-UHFFFAOYSA-N 0.000 claims 2
- WGRXIIODSLLFHX-UHFFFAOYSA-N 5-(2-fluorophenyl)-1-(4-fluorophenyl)quinolin-2-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=CC2=C(C=3C(=CC=CC=3)F)C=CC=C21 WGRXIIODSLLFHX-UHFFFAOYSA-N 0.000 claims 2
- OZRPUNDRYYIJFC-UHFFFAOYSA-N 6-bromo-1,5-bis(2-chlorophenyl)-7-methoxyquinolin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=C(Br)C(OC)=CC=2N1C1=CC=CC=C1Cl OZRPUNDRYYIJFC-UHFFFAOYSA-N 0.000 claims 2
- IGZZQGLWJPZOIX-UHFFFAOYSA-N 7-amino-1,5-bis(2-chlorophenyl)-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(N)=CC=2N1C1=CC=CC=C1Cl IGZZQGLWJPZOIX-UHFFFAOYSA-N 0.000 claims 2
- AHCYGXRBOJTSOA-UHFFFAOYSA-N 7-bromo-1,5-bis(2-chlorophenyl)-1,6-naphthyridin-2-one Chemical compound ClC1=CC=CC=C1C1=NC(Br)=CC2=C1C=CC(=O)N2C1=CC=CC=C1Cl AHCYGXRBOJTSOA-UHFFFAOYSA-N 0.000 claims 2
- CNFITDNLXNAZHQ-UHFFFAOYSA-N 7-bromo-1,5-bis(2-chlorophenyl)-3,4-dihydro-1,6-naphthyridin-2-one Chemical compound ClC1=CC=CC=C1N1C(C=C(Br)N=C2C=3C(=CC=CC=3)Cl)=C2CCC1=O CNFITDNLXNAZHQ-UHFFFAOYSA-N 0.000 claims 2
- HYXWKBBZPPNFRK-UHFFFAOYSA-N 7-chloro-1,5-bis(2-chlorophenyl)-1,6-naphthyridin-2-one Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(Cl)=CC=2N1C1=CC=CC=C1Cl HYXWKBBZPPNFRK-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 2
- IURAJLZDFDIJDK-UHFFFAOYSA-N n-[2-[[1,5-bis(2-chlorophenyl)-2-oxo-1,6-naphthyridin-7-yl]amino]ethyl]acetamide Chemical compound O=C1C=CC=2C(C=3C(=CC=CC=3)Cl)=NC(NCCNC(=O)C)=CC=2N1C1=CC=CC=C1Cl IURAJLZDFDIJDK-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- GMGXDNHBKGSSGN-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-(1,3-dihydroxypropan-2-ylamino)-1,8-naphthyridin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=NC(NC(CO)CO)=CC=1C1=CC=CC=C1Cl GMGXDNHBKGSSGN-UHFFFAOYSA-N 0.000 claims 1
- LNDRWHWANLOMIC-UHFFFAOYSA-N 1,5-bis(2-chlorophenyl)-7-[2-(propan-2-ylamino)ethylamino]-1,8-naphthyridin-2-one Chemical compound C=12C=CC(=O)N(C=3C(=CC=CC=3)Cl)C2=NC(NCCNC(C)C)=CC=1C1=CC=CC=C1Cl LNDRWHWANLOMIC-UHFFFAOYSA-N 0.000 claims 1
- RKISHQNZYVTTPG-UHFFFAOYSA-N 1,5-diphenyl-1,6-naphthyridin-2-one Chemical compound O=C1C=CC2=C(C=3C=CC=CC=3)N=CC=C2N1C1=CC=CC=C1 RKISHQNZYVTTPG-UHFFFAOYSA-N 0.000 claims 1
- PNBNHPIRIQEGTR-UHFFFAOYSA-N 1-benzyl-5-phenyl-1,6-naphthyridin-2-one Chemical compound O=C1C=CC2=C(C=3C=CC=CC=3)N=CC=C2N1CC1=CC=CC=C1 PNBNHPIRIQEGTR-UHFFFAOYSA-N 0.000 claims 1
- PIOGKVWSMAZIFA-UHFFFAOYSA-N 1-methyl-5-phenyl-1,6-naphthyridin-2-one Chemical compound C=12C=CC(=O)N(C)C2=CC=NC=1C1=CC=CC=C1 PIOGKVWSMAZIFA-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- APKKZTGSYROVPP-UHFFFAOYSA-N 5-phenyl-1h-1,6-naphthyridin-2-one Chemical compound N1=CC=C2NC(=O)C=CC2=C1C1=CC=CC=C1 APKKZTGSYROVPP-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44741003P | 2003-02-14 | 2003-02-14 | |
| US53809504P | 2004-01-21 | 2004-01-21 | |
| PCT/US2004/004406 WO2004073628A2 (en) | 2003-02-14 | 2004-02-13 | Novel compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517976A JP2006517976A (ja) | 2006-08-03 |
| JP2006517976A5 true JP2006517976A5 (https=) | 2008-10-09 |
Family
ID=32912260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006503591A Pending JP2006517976A (ja) | 2003-02-14 | 2004-02-13 | 新規化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7550480B2 (https=) |
| EP (1) | EP1596860A4 (https=) |
| JP (1) | JP2006517976A (https=) |
| AU (1) | AU2004212957A1 (https=) |
| CA (1) | CA2515939A1 (https=) |
| MX (1) | MXPA05008612A (https=) |
| PL (1) | PL378111A1 (https=) |
| WO (1) | WO2004073628A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29440A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| UY29439A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| ES2524922T3 (es) | 2005-05-10 | 2014-12-15 | Intermune, Inc. | Derivados de piridona para modular el sistema de proteína cinasa activada por estrés |
| WO2008001929A1 (en) | 2006-06-28 | 2008-01-03 | Aska Pharmaceutical Co., Ltd. | Treatment agent for inflammatory bowel disease |
| US8309138B2 (en) | 2007-02-16 | 2012-11-13 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| EP2291376A2 (en) * | 2008-07-03 | 2011-03-09 | Merck Patent GmbH | Naphthyridininones as aurora kinase inhibitors |
| CN103034654B (zh) * | 2011-10-10 | 2016-06-15 | 中国电信股份有限公司 | 社会化动态消息呈现控制方法及系统 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| EP3205645B1 (en) * | 2014-04-18 | 2019-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| DK3307262T3 (da) | 2015-06-15 | 2021-08-09 | Nmd Pharma As | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US12440477B2 (en) | 2017-12-14 | 2025-10-14 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN116669726A (zh) * | 2020-12-29 | 2023-08-29 | 谛希诺生物科技有限公司 | 对外核苷酸焦磷酸酶-磷酸二酯酶具有抑制活性的新颖的萘啶酮衍生物及其用途 |
| WO2022146022A1 (ko) * | 2020-12-29 | 2022-07-07 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
| JPWO2023195529A1 (https=) * | 2022-04-08 | 2023-10-12 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA966134A (en) * | 1972-05-05 | 1975-04-15 | Haydn W.R. Williams | 1,8-naphthyridine compounds |
| US3962262A (en) * | 1973-04-11 | 1976-06-08 | Merck & Co., Inc. | 1,8-naphthyridine compounds |
| US4031103A (en) * | 1974-06-07 | 1977-06-21 | Merck Sharp & Dohme (I.A.) Corporation | 1,8-Naphthyridine compounds |
| ZA803539B (en) * | 1979-06-14 | 1982-01-27 | Wellcome Found | Alkoxybenzylrimidines method for their preparation formulation thereof and their use in medicine |
| PT79699B (en) * | 1983-12-22 | 1986-12-10 | Pfizer | Process for preparing quinolone inotropic agents |
| US4560691A (en) * | 1984-07-13 | 1985-12-24 | Sterling Drug Inc. | 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation |
| US4650806A (en) * | 1985-01-14 | 1987-03-17 | Sterling Drug Inc. | Cardiotonic 5-(heterylcarbonyl)-pyridones |
| US4567186A (en) * | 1985-01-14 | 1986-01-28 | Sterling Drug Inc. | 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor |
| NZ214837A (en) * | 1985-01-28 | 1988-10-28 | Sterling Drug Inc | 5-substituted 1,6 naphthyridin-2(1h)-ones |
| AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
| JPH01261306A (ja) | 1988-04-13 | 1989-10-18 | Nippon Kayaku Co Ltd | ２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤 |
| DE3911064A1 (de) * | 1989-04-06 | 1990-10-11 | Bayer Ag | Substituierte 1,8-naphthyridine |
| US5409930A (en) * | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE4131029A1 (de) * | 1991-09-18 | 1993-07-29 | Basf Ag | Substituierte pyrido (2,3-d) pyrimidine als antidots |
| US5426110A (en) * | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
| US5547954A (en) * | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
| KR970705562A (ko) * | 1994-08-29 | 1997-10-09 | 오노다 마사요시 | 신규한 나프티리딘 유도체 및 이의 의약 조성물(Novel naphthyridine derivatives and medicinal composition thereof) |
| US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6875769B2 (en) * | 1996-05-23 | 2005-04-05 | Pfizer Inc. | Substituted6,6-hetero-bicyclicderivatives |
| US5989588A (en) * | 1996-10-04 | 1999-11-23 | Merck & Co., Inc. | Methods and compositions for preventing and treating heartburn |
| US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| BR9908004A (pt) * | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| EP1276737A1 (en) * | 2000-04-28 | 2003-01-22 | Pfizer Products Inc. | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) |
| EP1345603A4 (en) * | 2000-12-20 | 2004-09-08 | Merck & Co Inc | (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS |
| JP4178783B2 (ja) | 2001-10-19 | 2008-11-12 | 三菱化学株式会社 | 光学記録媒体 |
-
2004
- 2004-02-13 PL PL378111A patent/PL378111A1/pl not_active Application Discontinuation
- 2004-02-13 MX MXPA05008612A patent/MXPA05008612A/es unknown
- 2004-02-13 CA CA002515939A patent/CA2515939A1/en not_active Abandoned
- 2004-02-13 US US10/545,565 patent/US7550480B2/en not_active Expired - Fee Related
- 2004-02-13 JP JP2006503591A patent/JP2006517976A/ja active Pending
- 2004-02-13 EP EP04711237A patent/EP1596860A4/en not_active Withdrawn
- 2004-02-13 AU AU2004212957A patent/AU2004212957A1/en not_active Abandoned
- 2004-02-13 WO PCT/US2004/004406 patent/WO2004073628A2/en not_active Ceased
-
2009
- 2009-05-15 US US12/466,401 patent/US20090239897A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006517976A5 (https=) | ||
| CA2328780C (en) | Dihydropyrimidines | |
| AU2013307328B2 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis B | |
| US6245770B1 (en) | Fungicidal pyrimidinones | |
| AU2016417542B2 (en) | Imidazopyridine thioglycolic acid derivative, preparation method therefor and application thereof | |
| JP2003525295A5 (https=) | ||
| KR102346508B1 (ko) | 키나제 억제제로서 유용한 치환된 테트라히드로카르바졸 및 카르바졸 카르복스아미드 화합물 | |
| JP2007500715A5 (https=) | ||
| EP3013815B1 (en) | Carbazole carboxamide compounds useful as kinase inhibitors | |
| JP2013504593A5 (https=) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| NZ259114A (en) | Pyrazolopyrimidines and pharmaceutical compositions thereof | |
| AU2015335694A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| CZ20022390A3 (cs) | Antagonisty faktoru uvolňujícího kortikotropin | |
| CA2498051A1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
| KR20120120271A (ko) | 치환된 이미다조피리디닐-아미노피리딘 화합물 | |
| KR20120124428A (ko) | 치환된 피롤로-아미노피리미딘 화합물 | |
| JP2016540803A5 (https=) | ||
| JP2017512786A5 (https=) | ||
| JP2006507355A5 (https=) | ||
| JP2020500869A5 (https=) | ||
| JP2005530811A5 (https=) | ||
| JP2018526419A5 (https=) | ||
| JP2006508979A5 (https=) | ||
| TW200911802A (en) | 7-alkynyl-1,8-naphthyridone derivatives, preparation thereof and therapeutic use thereof |